US3635985A - 3-phenyl-4-acyloxycarbostyrils - Google Patents

3-phenyl-4-acyloxycarbostyrils Download PDF

Info

Publication number
US3635985A
US3635985A US6316A US3635985DA US3635985A US 3635985 A US3635985 A US 3635985A US 6316 A US6316 A US 6316A US 3635985D A US3635985D A US 3635985DA US 3635985 A US3635985 A US 3635985A
Authority
US
United States
Prior art keywords
phenyl
acyloxycarbostyrils
acetoxycarbostyril
sec
ethoxycarbonyloxycarbostyril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US6316A
Inventor
Haruki Nishimura
Yasutaka Nagai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dainippon Pharmaceutical Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Application granted granted Critical
Publication of US3635985A publication Critical patent/US3635985A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4

Definitions

  • R is methyl or ethoxy prepared by treating 3- phenyl-4-hydrocarbostyril with an acylating agent, which is useful as a minor tranquilizer with less side eifect and low toxicity.
  • the present invention relates to 3-phenyl-4-acyloxycarbostyrils, and their production and use.
  • the said 3-phenyl-4-acyloxycarbostyrils are representable by the formula:
  • R is methyl or ethoxy and include specifically 3- phenyl-4-acetoxycarbostyril and 3 phenyl-4-ethoxycarbonyloxycarbostyril.
  • 3-phenyl-4-acyloxycarbostyrils [I] exert a taming effect in fighting mice.
  • mice of dd strain weighing 18 to 20 g. each were used and divided into 5 groups each consisting of a pair. Two mice were put on an electrical stimulator and a 200 ml. beaker was placed upside down over the mice. Electric stimulation was given at the intervals of 7 sec. (540 v., 3 ma.). The time until two mice began to fight was measured with a timer at various times after administration of the test compound and calculated in terms of the score of 1 to 9 respectively for 0 to 5 sec., 6 to 10 sec., 11 to 15 sec., 16 to 20 sec., 21 to 25 sec., 26 to 30 sec., 31 to 35 sec., 36 to 40 sec. and more than 40 sec. The dosage showing an average mark of 5 was taken as ED Results ED (mg/kg,
  • Test compound per os) 3phenyl-4-acetoxycarbostyril 11.5 3-phenyl-4-ethoxycarbonyloxycarbostyril 10.5 3-phenyl-4-hydroxycarbostyril 100 3-phenyl-4-propionyloxycarbostyril 96.0 3-phenyl-4-phenacetyloxycarbostyril 100 3-phenyl-4-benzoyloxycarbostyril 100 3-phenyl-4-propoxycarbonyloxycarbostyril 96.0 3-phenyl-4-phenyloxycarbonyloxycarbostyril 100 1-ethyl-3-phenyl-4-acetoxycarbostyril 100 1-ethyl-3-phenyl-4-ethoxycarbonyloxycarbostyril 100 1-methyl-3-phenyl-4-hydroxycarbostyril 100 1-ethyl-3-phenyl-4-hydroxycarbostyril 100 chlordiazepoxide 18.0
  • the 3-phenyl-4- acyloxycarbostyrils [I] are less effective in muscle relaxation, which is considered as an unfavorable side action for the use of tanquilizers.
  • the ED values of 3-phenyl-4-acetoxycarbostyril and 3-phenyl-4-ethoxycarbonyloxycarbostyril are respectively 113.0 and 117.0 mg./kg. whereas the ED value of chlordiazepoxide is 45.3 mg./kg.
  • the toxicity of the 3-phenyl- 4-acyloxycarbostyrils [I] is extremely low.
  • the LD values of 3-phenyl-4-acetoxycarbostyril and 3-phenyl-4-ethoxycarbonyloxycarbostyril are both more than 3,000 mg./kg.
  • the LD value of chlordiazepoxide is 1,325 mg./kg.
  • 3-phenyl-4-acyloxycarbostyrils [I] of the present invention are useful as minor tranquilizers with less side effect and low toxicity.
  • a clinical dosage of the 3-phenyl-4-acyloxycarbostyrils [I] depends on disease syndrome, body weight, age and administration mode, but it is generally in the range of 0.05 to 500 mg./day, preferably of 0.5 to 200 mg./day. They can be used in a unit dosage form as tablets or capsules for oral administration or optionally in combination with suitable adjuvants such as calcium carbonate, starch, lactose, talc, magnesium stearate, carboxymethyl cellulose and gum acacia. Further, they can be formulated into aqueous alcohol, glycol, oil solutions or oil-water emulsions for oral administration in the same manner as conventional medical substances are formulated.
  • the 3-phenyllacyloxycarbostyril [I] is prepared by subjecting 3-phenyl- 4-hydroxycarbostyril of the formula:
  • the acylation may be accomplished in one or two steps.
  • the 3-phenyl-4-hydroxycarbostyril [II] or its monoalkali metal salt is treated with the reactive derivative of acetic acid or of carbonic acid ethyl ester in the presence or absence of a basic catalyst such as organic tertiary amine (e.g. pyridine, triethylamine, dimethylaniline) at a temperature from to 200 C., preferably from to 120 C.
  • a basic catalyst such as organic tertiary amine (e.g. pyridine, triethylamine, dimethylaniline)
  • the reactive derivative may be acid halide, acid anhydride, nitrophenyl ester, thiocyanate, dithiocarbamate, trithiophosphonate or the like.
  • an inert organic solvent e.g. benzene, toluene, dioxane, carbon tetrachloride.
  • the 3-phenyl-4-hydroxycarbostyril [II] or its monoalkali metal salt e.g. sodium salt, potassium salt
  • phosgene or nitro-substituted phenoxycarbonyl chloride e.g. p-nitrophenoxycarbonyl chloride
  • an inert organic solvent e.g. dichloromethane, chloroform, dioxane, tetrahydrofuran
  • the above materials are mixed together, granulated and tableted in accordance with a conventional method to give 2,000 tablets, each weighing 50 mg.
  • R is methyl or ethoxy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

A 3-PHENYL-4-ACYLOXYCARBOSTYRIL OF THE FORMULA:

2-(O=),3-PHENYL,4-(R-COO-)-1,2-DIHYDROQUINOLINE

WHEREIN R IS METHYL OR ETHOXY PREPARED BY TREATING 3PHENYL-4-HYDROCARBOXTYRIL WITH AN ACYLATING AGENT, WHICH IS USEFUL AS A MINOR TRAQUILIZER WITH LESS SIDE EFFECT AND LOW TOXICITY.

Description

United States Patent 3,635,985 S-PHENYL-4-ACYLOXYCARBOSTYRILS Haruki Nishimura, Osaka-fu, and Yasutaka Nagai, Kyotofu, Japan, assiguors to Dainippon Pharmaceutical Co.,
Ltd., Higashi-ku, Osaka-shi, Osaka-fu, Japan N0 Drawing. Filed Jan. 27, 1970, Ser. No. 6,316 Claims priority, application Japan, Feb. 1, 1969, 44/7,498 Int. Cl. C07d 33/48 U.S. Cl. 260--287 R 3 Claims ABSTRACT OF THE DISCLOSURE A 3phenyl-4-acyloxycarbostyril of the formula:
wherein R is methyl or ethoxy prepared by treating 3- phenyl-4-hydrocarbostyril with an acylating agent, which is useful as a minor tranquilizer with less side eifect and low toxicity.
The present invention relates to 3-phenyl-4-acyloxycarbostyrils, and their production and use.
The said 3-phenyl-4-acyloxycarbostyrils are representable by the formula:
wherein R is methyl or ethoxy and include specifically 3- phenyl-4-acetoxycarbostyril and 3 phenyl-4-ethoxycarbonyloxycarbostyril.
The 3-phenyl-4-acyloxycarbostyrils [I] exert a taming effect in fighting mice. The test results on 3-phenyl-4- acetoxycarbostyril [I:R=CH and 3-phenyl-4-ethoxycarbonyloxycarbostyril [I:R=C H O] as well as some structurally related compounds and a commercially available minor tranquilizer, chlordiazepoxide, are shown below.
Test method Ten male mice of dd strain weighing 18 to 20 g. each were used and divided into 5 groups each consisting of a pair. Two mice were put on an electrical stimulator and a 200 ml. beaker was placed upside down over the mice. Electric stimulation was given at the intervals of 7 sec. (540 v., 3 ma.). The time until two mice began to fight was measured with a timer at various times after administration of the test compound and calculated in terms of the score of 1 to 9 respectively for 0 to 5 sec., 6 to 10 sec., 11 to 15 sec., 16 to 20 sec., 21 to 25 sec., 26 to 30 sec., 31 to 35 sec., 36 to 40 sec. and more than 40 sec. The dosage showing an average mark of 5 was taken as ED Results ED (mg/kg,
Test compound: per os) 3phenyl-4-acetoxycarbostyril 11.5 3-phenyl-4-ethoxycarbonyloxycarbostyril 10.5 3-phenyl-4-hydroxycarbostyril 100 3-phenyl-4-propionyloxycarbostyril 96.0 3-phenyl-4-phenacetyloxycarbostyril 100 3-phenyl-4-benzoyloxycarbostyril 100 3-phenyl-4-propoxycarbonyloxycarbostyril 96.0 3-phenyl-4-phenyloxycarbonyloxycarbostyril 100 1-ethyl-3-phenyl-4-acetoxycarbostyril 100 1-ethyl-3-phenyl-4-ethoxycarbonyloxycarbostyril 100 1-methyl-3-phenyl-4-hydroxycarbostyril 100 1-ethyl-3-phenyl-4-hydroxycarbostyril 100 chlordiazepoxide 18.0
From the above table, it is seen that 3-phenyl-4-acetoxycarbostyril and 3-penyl-4-ethoxycarbonyloxycarbostyril show a higher taming effect than chlordiazepoxide, whereas other structurally related compounds exhibit no material or only slight effect.
In addition, it is advantageous that the 3-phenyl-4- acyloxycarbostyrils [I] are less effective in muscle relaxation, which is considered as an unfavorable side action for the use of tanquilizers. For instance, when orally administered to mice, the ED values of 3-phenyl-4-acetoxycarbostyril and 3-phenyl-4-ethoxycarbonyloxycarbostyril are respectively 113.0 and 117.0 mg./kg. whereas the ED value of chlordiazepoxide is 45.3 mg./kg.
It is also advantageous that the toxicity of the 3-phenyl- 4-acyloxycarbostyrils [I] is extremely low. For instance, when the acute toxicity is determined by administering orally to mice, the LD values of 3-phenyl-4-acetoxycarbostyril and 3-phenyl-4-ethoxycarbonyloxycarbostyril are both more than 3,000 mg./kg., Whereas the LD value of chlordiazepoxide is 1,325 mg./kg.
Thus, the 3-phenyl-4-acyloxycarbostyrils [I] of the present invention are useful as minor tranquilizers with less side effect and low toxicity.
A clinical dosage of the 3-phenyl-4-acyloxycarbostyrils [I] depends on disease syndrome, body weight, age and administration mode, but it is generally in the range of 0.05 to 500 mg./day, preferably of 0.5 to 200 mg./day. They can be used in a unit dosage form as tablets or capsules for oral administration or optionally in combination with suitable adjuvants such as calcium carbonate, starch, lactose, talc, magnesium stearate, carboxymethyl cellulose and gum acacia. Further, they can be formulated into aqueous alcohol, glycol, oil solutions or oil-water emulsions for oral administration in the same manner as conventional medical substances are formulated.
According to the present invention, the 3-phenyllacyloxycarbostyril [I] is prepared by subjecting 3-phenyl- 4-hydroxycarbostyril of the formula:
H [II] to acylation. The acylation may be accomplished in one or two steps.
When carried out in one step, the 3-phenyl-4-hydroxycarbostyril [II] or its monoalkali metal salt (e.g. sodium salt, potassium salt) is treated with the reactive derivative of acetic acid or of carbonic acid ethyl ester in the presence or absence of a basic catalyst such as organic tertiary amine (e.g. pyridine, triethylamine, dimethylaniline) at a temperature from to 200 C., preferably from to 120 C. The reactive derivative may be acid halide, acid anhydride, nitrophenyl ester, thiocyanate, dithiocarbamate, trithiophosphonate or the like. If necessary, there may be employed as the reaction medium an inert organic solvent (e.g. benzene, toluene, dioxane, carbon tetrachloride).
When carried out in two steps, the 3-phenyl-4-hydroxycarbostyril [II] or its monoalkali metal salt (e.g. sodium salt, potassium salt) is first reacted with phosgene or nitro-substituted phenoxycarbonyl chloride (e.g. p-nitrophenoxycarbonyl chloride) in an inert organic solvent (e.g. dichloromethane, chloroform, dioxane, tetrahydrofuran) at a temperature from -10 to C. and the resultant 4-chlorocarbonyloxy compound is then reacted with ethanol in the presence of a basic substance such as alkali metal (e.g. sodium, potassium) or alkoxide of alkali metal (e.g. sodium ethoxide) at a temperature from 10 to 60 C. to obtain the 3-phenyl-4-acyloxycarbostyril [I1 Practical and presently preferred embodiments of th present invention are illustratively shown in the following examples.
EXAMPLE 1 Preparation of 3-phenyl-4-acetoxycarbostyril A mixture of 3-phenyl-4-hydroxycarbostyril (5 g.), acetic anhydride ml.) and pyridine (0.5 ml.) is heated on an oil bath at 120 to 140 C. for 2 hours. The reaction mixture is allowed to stand at room temperature overnight and concentrated under reduced pressure to remove acetic anhydride. The residue is recrystallized from methanol to give 3-phenyl-4-acetoxycarbostyril (4.2 g.) as crystals melting at 252 to 254 C.
EXAMPLE 2 Preparation of 3-phenyl-4-acetoxycarbostyril A mixture of 3-phenyl-4-hydroxycarbostyril (2 g.), pyridine (20 ml.) and acetyl chloride (2.5 g.) is heated on a water bath for 2 hours. The reaction mixture is allowed to stand at room temperature overnight and concentrated under reduced pressure to remove pyridine. The residue is recrystallized from methanol to give 3-phenyl- 4-acetoxycarb0styril (1.9 g.) as crystals melting at 252 to 254 C.
4 EXAMPLE 3 Preparation of 3-phenyl-4-ethoxycarbonyloxycarbostyril EXAMPLE 4 Materials: Grams 3 phenyl 4-ethoxycarbonyloxycarbostyril 5 Lactose Starch 9.5 Microcrystalline cellulose 20 Magnesium stearate 0.5
The above materials are mixed together, granulated and tableted in accordance with a conventional method to give 2,000 tablets, each weighing 50 mg.
What is claimed is:
1. A 3-phenyl-4-acyloxycarbostyril of the formula:
OCOR
wherein R is methyl or ethoxy.
2. 3-phenyl-4-acetoxycarbostyril. 3. 3-phenyl-4-ethoxycarbonyloxyearbostyril.
References Cited UNITED STATES PATENTS 3,542,785 11/1970 Carney 260-289 FOREIGN PATENTS 1,121,411 7/1968 Great Britain 260289 DONALD G. DAUS, Primary Examiner U.S. Cl. X.R.
US6316A 1969-02-01 1970-01-27 3-phenyl-4-acyloxycarbostyrils Expired - Lifetime US3635985A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP749869 1969-02-01

Publications (1)

Publication Number Publication Date
US3635985A true US3635985A (en) 1972-01-18

Family

ID=11667424

Family Applications (1)

Application Number Title Priority Date Filing Date
US6316A Expired - Lifetime US3635985A (en) 1969-02-01 1970-01-27 3-phenyl-4-acyloxycarbostyrils

Country Status (7)

Country Link
US (1) US3635985A (en)
BE (1) BE745289A (en)
CH (1) CH529760A (en)
DE (1) DE2003840A1 (en)
DK (1) DK122127B (en)
FR (1) FR2030240B1 (en)
GB (1) GB1252861A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994900A (en) * 1976-01-23 1976-11-30 E. R. Squibb & Sons, Inc. 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones
US4168312A (en) * 1976-11-12 1979-09-18 Merck Patent Gesellschaft Mit Beschrankter Haftung Quinolone derivatives
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994900A (en) * 1976-01-23 1976-11-30 E. R. Squibb & Sons, Inc. 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones
US4168312A (en) * 1976-11-12 1979-09-18 Merck Patent Gesellschaft Mit Beschrankter Haftung Quinolone derivatives
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors

Also Published As

Publication number Publication date
DK122127B (en) 1972-01-24
FR2030240A1 (en) 1970-11-13
DE2003840A1 (en) 1970-07-30
CH529760A (en) 1972-10-31
BE745289A (en) 1970-07-01
FR2030240B1 (en) 1974-06-14
GB1252861A (en) 1971-11-10

Similar Documents

Publication Publication Date Title
SU1072803A3 (en) Process for preparing derivatives of phthalazin-4-yl acetic acid or their salts
PT91580B (en) PROCESS FOR THE PREPARATION OF N-SUBSTITUTE NON-SUBSTITUTE NICOTINAMIDE COMPOUNDS
JPS60243017A (en) Antispasmodic composition
GB2196962A (en) Substituted 2-benzyl-mercapto-imidazoles and analogs useful as anti-inflammatory agents
US3553258A (en) Phenylalanine compounds
US3635985A (en) 3-phenyl-4-acyloxycarbostyrils
JPS5925794B2 (en) Heterocyclylcarbonyl derivatives of urea
US4590205A (en) Antiinflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes
EP0087629A2 (en) Antiinflammatory and/or analgesic 2,3-Diaryl-5-halo thiophenes
US2895877A (en) Composition and method for relieving spasticity
US3177211A (en) 10-[(aminocarbamyl-1-piperidyl)-loweralkyl]-phenothiazines
DE2952594A1 (en) DISULFID COMPOUNDS
US3580910A (en) P-alkoxy-piperidine-amides
JPS5646810A (en) Blood platelet coagulation inhibitor
US3836658A (en) Tri-substituted imidazoles in the treatment of gout
US4774241A (en) Derivative of benzoquinonylphenyl alkanoic acid amide
US4182775A (en) Benzoic acids and process for their preparation
GB1561521A (en) 3,4 - dihydro - 3 - oxo - 4-carbamoyl - 2h - thieno (2,3 - e) - 1 - 2-thiazine 1,1 - dioxide derivatives
JPH0560478B2 (en)
US3622610A (en) Sulfonate esters of gallic acid derivatives
US3886279A (en) Anti-inflammatory analgesic method of treatment and composition
EP0204172B1 (en) Phenylpyrazine derivatives, processes for preparing them, pharmaceutical composition and use
US3497501A (en) Heterocyclic amino esters of 2-phenylacrylic acid
FR2361386A1 (en) NEW HETEROCYCLIC COMPOUNDS OF THE TETRAHYDRO-4-OXO-4 H-NAPHTO TYPE SUBSTITUTES, THEIR PREPARATION PROCESS AND THE MEDICINAL PRODUCT CONTAINING THEM
JPH01308227A (en) Protease inhibitor